Former Moderna executives Evan Rachlin and Lorence Kim closed Ascenta Capital’s inaugural fund at $325 million to invest in platform‑stage biotechs. The firm targets indication‑agnostic, multi‑asset platforms—RNA, oncology, immunology and beyond—with a hands‑on approach to clinical, regulatory and manufacturing strategy. Ascenta’s portfolio already includes RNA‑editing and oncology companies; the fundraise reflects renewed VC appetites for platform plays and deep‑tech bets amid a rebound in biotech financings.